持续性化疗诱导脱发的预防、诊断与管理专家共识
该专家共识采用两轮德尔菲法,由15名国际支持性肿瘤皮肤病学与毛发疾病专家参与,定义了持续性化疗诱导脱发(pCIA)为化疗后6个月以上持续存在的非瘢痕性脱发,并达成47条(75.8%)强共识声明,涵盖预防、诊断分级和管理推荐。共识强调头皮冷却预防和早期局部或低剂量口服米诺地尔干预,但不推荐对乳腺癌pCIA患者使用比卡鲁胺、口服非那雄胺和度他雄胺。
要点
- pCIA定义为化疗后6个月以上持续的非瘢痕性脱发。
- 推荐头皮冷却设备预防pCIA,早期局部或低剂量口服米诺地尔干预。
- 乳腺癌pCIA患者不推荐比卡鲁胺、口服非那雄胺和度他雄胺。
核心结论
- 该德尔菲研究建立了pCIA的统一指南,为临床医生提供了清晰的诊断和治疗框架。
- 强调通过头皮冷却预防和及时干预可能改善癌症幸存者的结局。
- 需要进一步研究评估新疗法和化疗对毛囊的长期影响。
研究设计与样本
- 采用两轮德尔菲法,由来自欧洲和美洲的15名支持性肿瘤皮肤病学和毛发疾病国际专家参与。
- 声明采用5点李克特量表评分,强共识定义为≥75%同意率;第一轮未达强共识的声明根据专家反馈修订后第二轮重新评估。
主要发现
- 47条声明(75.8%)达到强共识。
- pCIA被定义为化疗后6个月以上持续存在的非瘢痕性脱发。
- 病因归因于毛囊干细胞破坏,紫杉烷类、噻替派和蒽环类药物被确定为关键贡献者。
关键数值与推荐
- 强共识定义为≥75%同意率。
- pCIA定义为化疗后6个月以上持续的非瘢痕性脱发。
- 共识强调通过头皮冷却设备预防pCIA,并推荐早期使用局部或低剂量口服米诺地尔干预。
- 专家不推荐对乳腺癌pCIA患者使用比卡鲁胺、口服非那雄胺和度他雄胺(包括中胚层疗法), citing潜在安全问题。
临床怎么用
- 临床医生可依据共识定义的pCIA诊断标准(化疗后6个月以上持续非瘢痕性脱发)进行识别。
- 应重视头皮冷却设备用于预防pCIA,并考虑早期局部或低剂量口服米诺地尔干预。
- 对乳腺癌pCIA患者,应避免使用比卡鲁胺、口服非那雄胺和度他雄胺(包括中胚层疗法)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management. OBJECTIVES: To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA. METHODS: A two-round Delphi method was conducted with 15 international experts in supportive oncodermatology and hair diseases from both Europe and the Americas. Statements were rated on a 5-point Likert scale, with a strong consensus defined as ≥75% agreement. Statements that did not achieve strong consensus in the first round were revised based on expert feedback and re-evaluated in a second-round survey. RESULTS: Strong consensus was reached on 47 statements (75.8%). pCIA was defined as non-scarring alopecia persisting beyond 6 months post-chemotherapy. Causes were attributed to the destruction of hair follicle stem cells, with taxanes, thiotepa and anthracyclines identified as key contributors. Consensus emphasized the importance of prevention of pCIA through scalp cooling devices, and the early intervention with topical or low-dose oral minoxidil was also recommended. Interestingly, the experts did not recommend the use of bicalutamide, oral finasteride and dutasteride (including in mesotherapy) for breast cancer patients with pCIA, citing potential safety concerns. CONCLUSIONS: This Delphi study established unified guidelines for pCIA, providing clinicians with a clear framework for diagnosis and treatment. Highlighting prevention through scalp cooling and timely interventions may improve outcomes for cancer survivors. Further research is necessary to assess new treatments and the long-term impact of chemotherapy on hair follicles.
引用
- Freites-Martinez A, Apalla Z, Shapiro J, et al. Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia. J Eur Acad Dermatol Venereol. 2025. PMID: 40923546. doi:10.1111/jdv.70021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。